- CEO
- Ping Chen
- Full Time Employees
- 1,155
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Shanghai China
- IPO Date
- Nov 1, 2022
- Business
- PharmaResources (Shanghai) Co., Ltd. is a China-based contract research, development, and manufacturing organization (CRO/CDMO) that provides integrated, end-to-end drug discovery, chemical process development, and commercial manufacturing services to the global pharmaceutical and biotechnology industries. Founded in 2007 and headquartered in Shanghai, China, the company operates primarily through three core business segments: Drug Discovery (CRO), Process Research and Development (CRO/CDMO), and Commercial Manufacturing (CDMO/CMO).
The company offers a comprehensive portfolio of products and technical services across the small molecule drug development lifecycle, including: drug discovery services comprising target validation, hit-to-lead identification, lead optimization, custom organic synthesis, medicinal chemistry, structure-based and ligand-based drug design, in vitro and in vivo drug metabolism and pharmacokinetics (DMPK) evaluations, and preliminary safety profiling; artificial intelligence-driven drug discovery (AIDD) and computer-aided drug design (CADD) through its proprietary DiOrion platform, featuring modules such as DiOrion-PepGen for cyclic peptide engineering and the DiOrion-GPT biomedical language model for target identification and molecular optimization across complex modalities including antibody-drug conjugates (ADCs) and proteolysis targeting chimeras (PROTACs); process chemistry and development services encompassing synthetic route scouting, reaction engineering, process safety assessment, polymorphic form screening, crystallization process development, analytical method development and validation, and flow chemistry technology application for hazardous or complex reaction conditions; and cGMP-compliant commercial production of registered starting materials (RSMs), advanced regulatory intermediates, and active pharmaceutical ingredients (APIs) ranging from kilogram to multi-ton scales, supporting commercial products and development-stage compounds such as ticagrelor, oxiracetam, L-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2.
PharmaResources serves innovative biopharmaceutical companies, multinational pharmaceutical corporations, and research institutions across North America, Europe, and the Asia-Pacific region. The company conducts its research, development, and administrative activities across multiple sites in Shanghai and Chengdu, while operating large-scale cGMP manufacturing facilities through its primary production subsidiary, PharmaResources (Kaiyuan) Pharmaceutical Co., Ltd. in Liaoning Province, equipped with more than 120 reaction vessels ranging in capacity from 200 liters to 10,000 liters. The company also maintains international customer service, business development, and project management operations via its overseas subsidiary, PharmaResources, LLC, located in the United States.
In recent developments, PharmaResources has completed the construction and operational transition of its Phase II and Phase III preclinical new drug research and development base expansion projects, substantially increasing laboratory capacity by adding specialized CDMO facilities in Shanghai and expanded medicinal chemistry and DMPK research space in Chengdu. The company is actively executing a commercial manufacturing capacity ramp-up at its Kaiyuan production facility, deploying modular continuous flow microchannel reaction platforms to enhance throughput, safety, and cost efficiency for energetic and complex chemistries. Furthermore, PharmaResources has expanded the deployment of its proprietary DiOrion AI platform, integrating multi-modal AI models directly with internal wet-lab synthesis and biological testing workflows to support more than one hundred external collaborative drug discovery programs. The company has also completed corporate governance adjustments and capital restructuring initiatives, including equity distribution and capital reserve transfers, to support ongoing operational scaling and expanded international service engagements.